KVUE logo

Kenvue Inc. Stock Price

NYSE:KVUE Community·US$36.6b Market Cap
  • 2 Narratives written by author
  • 0 Comments on narratives written by author
  • 118 Fair Values set on narratives written by author

KVUE Share Price Performance

US$19.05
-2.85 (-13.01%)
US$19.50
Fair Value
US$19.05
-2.85 (-13.01%)
2.3% undervalued intrinsic discount
US$19.50
Fair Value
Price US$19.05
AnalystConsensusTarget US$19.50
julio US$25.09

KVUE Community Narratives

·
Fair Value US$19.5 2.3% undervalued intrinsic discount

Analyst Commentary Highlights Legal Risks and Valuation Adjustments for Kenvue Amid Market Uncertainty

0users have liked this narrative
0users have commented on this narrative
55users have followed this narrative
Fair Value
·
Fair Value US$25.09 24.1% undervalued intrinsic discount

J&J spinoff

1users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
KVUE logo
Kenvue

J&J spinoff

Bulls With autonomy from its former parent, Kenvue can allocate resources to best fit its needs and grow the business. Macro drivers like an aging population and premiumization of health care will act as tailwinds for all of Kenvue ’ s brands.Read more

View narrative
US$25.09
24.1% undervalued intrinsic discount
Fair Value
Revenue
8.7% p.a.
Profit Margin
13.3%
Future PE
24x
Price in 2034
US$59.35
US$19.5
2.3% undervalued intrinsic discount
Revenue
2.88% p.a.
Profit Margin
13.63%
Future PE
20.67x
Price in 2029
US$24.38

Trending Discussion

No trending discussion available.

Updated Narratives

KVUE logo

J&J spinoff

Fair Value: US$25.09 24.1% undervalued intrinsic discount
11 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
KVUE logo

KVUE: Future Returns Will Balance Kimberly-Clark Deal Timing And Execution Risks

Fair Value: US$19.5 2.3% undervalued intrinsic discount
55 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Proven track record and fair value.

2 Risks
3 Rewards

Kenvue Inc. Key Details

US$15.4b

Revenue

US$6.4b

Cost of Revenue

US$9.0b

Gross Profit

US$7.3b

Other Expenses

US$1.7b

Earnings

Last Reported Earnings
Jun 28, 2026
Next Reporting Earnings
n/a
0.86
58.44%
10.76%
79.1%
View Full Analysis

About KVUE

Founded
2022
Employees
21890
CEO
Kirk Perry
WebsiteView website
www.kenvue.com

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women’s health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee’s Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson’s, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson’s Baby, Johnson’s Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

Recent KVUE News & Updates

Recent updates

No updates